Sarah D Atkinson MD PLLC

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $387,263 13 payments
2. Sunovion Pharmaceuticals Inc. $185,884 6 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $131,159 19 payments
4. Pfizer Inc. $126,053 20 payments
5. Sage Therapeutics, Inc. $71,072 10 payments
6. ITI, Inc. $43,762 13 payments
7. H. Lundbeck A S $25,980 10 payments
8. ACADIA Pharmaceuticals Inc $6,172 2 payments

1. Pediatric Open-Label Extension Study $185,884 6 payments
2. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00014 $124,550 1 payment
3. A Long-Term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole As Maintenance Treatment in Adolescent Patients With Schizophrenia $102,324 1 payment
4. A Pilot Study of Digital Health Technology Assessments in Schizophrenia $68,610 16 payments
5. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $62,549 3 payments
6. A Phase 3 Multicenter Fourweek Randomized Doubleblind Placebocontrolled Parallelgroup Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Current Or Most Recent Episode Manic $52,047 3 payments
7. 26Week Openlabel Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Most Recent Episode Manic $47,096 10 payments
8. A Multicenter, Randomized, Double-Blind, Placebo-And Active-Controlledtrial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents 13-17 Years Old With Schizophrenia $43,203 1 payment
9. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder $35,881 1 payment
10. An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia $35,790 12 payments

1. Other $131,159 19 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.